UCB Biopharma
Allee De La Recherche 60
1070 Brussel (Anderlecht)
BE
UCB Biopharma
Foundation date
20/12/2013
Sector
#PharmaSubsector
Therapeutic areas
- #Diseases of the nervous system
- #Mental and behavioural disorders
- #Musculoskeletal system and connective tissue
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Bimekizumab Phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks
Monday March 20th 2023
Read more
-
VIB launches Data Core to support life sciences research
Thursday March 16th 2023
Read more
-
Aitia and UCB announce strategic drug discovery collaboration in Huntington's Disease
Thursday March 16th 2023
Read more
Jobs
More jobs-
21/03/23
Flemish Brabant
PhD position - Improved cytogenomic diagnosis in lymphoma: opportunities of optical genome mapping and long-read sequencing.
Temporary
KU Leuven -
21/03/23
Antwerp
Valorisation Manager for the IOF consortium IMARK, IOF platform for image-based biomarkers
Permanent
University of Antwerp -